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Randomised controlled trials (RCTs) are the work-horse of evidence-based health-
care and the only research design that can demonstrate causality i.e. that an 
intervention causes a direct change in a clinical outcome. Although they can be 
complex, the idea at its simplest is to “create two identical systems into one of which 
a new component [the intervention] is introduced”.1 Observations are then made of 
outcome differences that occur between experimental and control conditions and 
“should a change occur, it is attributed to the one difference between them” (Figure 
1).1 This paper aims to explain how to design a Randomised Controlled Trial for 
those who have little prior knowledge of the topic and specifically explore the 
following areas: will focus on some of the important issues of trial design and will 
cover:  
 
• The PICO statement 
• Randomisation 
• Trial design 
• Statistical testing 
• Sample size calculations 
• Bias 
• Clinical Trials Units 
 
Before you start: how do you ask the right question? 
Whether you are designing an individually randomised, cluster randomised, stepped 
wedge or adaptive trial, your research question always returns to your PICO 
statement. Precision in defining a research question is a key skill; the more precise 
the research question is, the easier it is to design your study. The PICO statement 
divides a research question into four basic parts: the patient/population (who are you 
intending to conduct the study with/on), the intervention, the control and the outcome 
measure. 
 
 P = Population 
The first step in developing a well-built question is to identify the patient problem or 
describe the population group of interest. When identifying the P in PICO it is helpful 
to ask yourself how you would describe this population group to another person. 
What are their important characteristics of the group? For example, this could be 
children, or more specifically young children under the age of five years of age. For 
example, in the Northern Ireland Caries Prevention In Practice (NIC-PIP) trial, the 
eligible population was caries free children aged between two and three years of age 
(Table 1).2 
 
I = Intervention 
Identifying the intervention is the second step in the PICO process. It is important to 
identify what you plan to do to your population. This may include the use of a specific 
diagnostic test, treatment, adjunctive therapy, medication or a recommendation to 
use a product or procedure. When thinking about conducting a randomised 
controlled trial, the intervention would be the health technology that you intend to test 
experimentally. In NIC-PIP, this was the delivery of a preventive regime in line with 
Delivering Better Oral Health. In the iQuaD trial, the intervention was personalised 
oral hygiene advice (Table 1).3 Some RCTs also employ more that one active arm 
simultaneously. For example, the FiCTION trial utilises two active arms: conventional 
caries management with best practice prevention and biological management of 
caries with best practice prevention (Table 1). 4 
 
I = Control or comparison 
The control or comparison is the third step to take in building your PICO question. 
This represents the alternative you are planning to compare the intervention to. This 
can take a number of forms. For example, it could be no active intervention. This is 
classically known as the “control group” in a RCT. For example, you might be 
comparing a new high fluoride toothpaste to prevent dental caries. However, it could 
equally refer to present current treatment. Here, the researcher would be testing a 
new intervention drug compared to existing treatment an old drug or two different 
types of intervention like Atraumatic Restorative Treatment versus the Hall 
Technique, in what is called a “head-to-head”.5 
 
O = Outcome 
Determining the primary outcome measure (POM) is the final step in building the 
PICO question and one of the most important as it has ramifications on how you 
statistically test for differences between the intervention and the control/comparator. 
It specifies what you would expect to see, should the intervention be successful. It is 
important to decide here whether your POM would be measured using this will be a 
continuous variable or an ordinal one. The difference between these two types of 
variables is that a continuous variable describes outcomes that are measured on a 
scale, like height or weight, whereas ordinal variables are categorical in nature and 
as the name suggests, can be placed in order. For example, if a person is asked 
about their feelings towards their dental care and the available responses are 
unsatisfied, neutral or satisfied, this would be an ordinal variable.  
 
Another key aspect to specify when thinking about your POM is its time to expression 
i.e. how quickly and when you would expect to see your result (which will be 
dependent on the “time-to-expression” of the intervention in your population). Time to 
expression has a critical influence on the duration of the trial (and thereby cost) and 
will obviously vary with the type of disease under investigation. For example, trials 
evaluating interventions for gingivitis will have a much shorter duration compared to 
caries trials. In the FiCTION trial, the research question is “what is the clinical and 
cost effectiveness of restoration caries in primary teeth, compared to no treatment?”. 
Here, the POM is the incidence of either pain or infection related to dental caries and 
the follow-up period is three years (Table 1). 
 
Why bother with randomisation? 
When a new RCT is being planned, researchers are said to be in equipoise. This 
means that we are uncertain whether the new treatment being experimentally tested 
actually produces a benefit for the participant. This is an ethical position. If we 
already have evidence that a new treatment is better than another, we should be 
giving this treatment to the patient already and if we know there is no difference or 
that the new treatment is harmful, we shouldn’t be offering it all to the patient. 
Consolidated Standards of Reporting Trials (CONSORT) 2010 states “ideally, 
participants should be assigned to comparison groups in the trial on the basis of a 
chance (random) process characterized by unpredictability.”6 The requirement is 
there for a reason. Randomisation of the participants is crucial because it allows the 
principles of statistical theory to stand and as such allows a thorough analysis of the 
trial data without bias.  
 
So, how do we randomise? Surely putting participants into random groups is as 
simple as tossing a coin? This is randomisation in its simplest form but in many 
cases it results in an unbalanced sample. For example, in a small trial of say 50 
participants, tossing a fair coin 50 times would result in a 25:25 split only 7.95% of 
the time!  
There are many different types of randomisation. Tossing a coin or using a random 
number table are examples of simple randomisation. Restricted randomisation uses 
methods to control the imbalance between the groups; generating a random list 
AAABBBABABAABB allows participants to be allocated as they arrive to the next 
treatment on the list. With the list here we know that at the sixth, eighth, tenth and 
14th participants we have balance in allocation. Stratified randomisation allows us to 
account for and control certain characteristics within the population of participants 
such as gender or age (factors that might confound the final effect). It is now 
recommended that stratification should be used sparingly and only in those 
characteristics that you think would potentially affect your outcome. With four 
stratification variables each with 2 levels, you would be dividing your sample into 42 
sub-samples and the question is then: how likely is it that each of those 16 
combinations would be fairly represented? Given that you never know which patient 
will walk through the door next, you could end up with a completely unbalanced 
design anyway. 
 
When choosing a randomisation method it is important to determine whether the 
method can accommodate enough treatment groups. For example, tossing a coin 
would be difficult to implement for a trial with three arms three group trial. It is also 
important to determine how predictable the method is. A deterministic algorithm (not 
considered randomisation) would allow you to be able to predict what treatment 
would be allocated next. A static random element would mean that each allocation is 
made with a pre-determined probability (tossing a coin gives a 50:50 chance of either 
treatment being assigned). A dynamic element adjusts the probability of being 
allocated to a treatment based on what has already been allocated in the trial so far. 
This is the basis of the North Wales Organisation for Randomised Trials in Health’s 
(NWORTH) remote randomisation system.7 
 
Other considerations include, can the method accommodate for stratification 
variables and if so, how many? Can the method handle an unequal allocation ratio? 
Is thresholding used (i.e. maximum level of accepted imbalance)? Can the method 
be implemented sequentially i.e. as the patients walk through your door? Is the 
method complex? Is the method suitable for cluster randomisation? Decisions like 
these mean that often a Clinical Trials Unit is needed in the design and planning of 
your trial. Further reading can be found here.8,9 
 
How do you go about designing your trial? 
There are different phases of RCTs. Phase I trials are described as “first into person”, 
whilst Phase II are slightly larger trials that commonly determine efficacy i.e. does the 
intervention work or not. Phase III trials take this a step further and determine 
effectiveness i.e. does the intervention produce health benefits in the real world. This 
section will focus on Phase III trial designs. Again, it is important that you consult a 
statistician at this stage: “to call in the statistician after the experiment is done may 
be no more than asking him to perform a post-mortem examination: he may be able 
to say what the experiment died of”.10 
 
Feasibility or pilot or full trial 
A key question to ask when designing a trial is do you have all the information to 
inform all the parameters needed. A feasibility study helps you determine whether a 
definitive trial is “feasible”. This type of study is often not randomised. This is 
because the intervention under study is commonly under development and the study 
plan or intervention itself would change before a definitive study is started. The 
important outcomes of a feasibility study will be things like the ability to recruit 
participants, ability to retain participants for the length of time required, the suitability 
of the proposed outcome measures, and willingness of the participants /clinicians to 
be involved.  
 
Pilot studies can be thought of as a small versions of the definitive trial i.e. your 
intervention is now established, but there is still some uncertainty about whether your 
definitive trial can run as planned. A pilot study will assess all the features that a 
feasibility study does and often the terms are used interchangeably. Further reading 
on the issue of terminology can be found here.11,12,13 With a stable intervention to test, 
enough information about the difference in the primary outcome measure POM you 
expect (known as the effect size), enough understanding about the time to 
expression of your chosen POM, confidence about the feasibility of running the trial 
as designed, then it may be time to design a definitive trial of the intended 
intervention.  
 
Randomised or non-randomised 
A RCT randomised controlled trial is seen as the ‘gold standard’ of trial design but 
there are some situations where randomisation is not possible for logistical or ethical 
reasons and so it can be acceptable to design a non-randomised trial. Uncontrolled 
or non-randomised trials are used when randomisation is not possible or is unethical. 
The results of non-randomised or uncontrolled trials may be considered less reliable 
as there is an increased risk for errors affecting the outcome of the trial. An example 
of a non-randomised trial is Lam et al’s (2010) study of mental-health first aid 
training.14 The “SPIRIT 2013 Statement” provides recommendations for a minimum 
set of scientific, ethical, and administrative elements that should be addressed in a 
clinical trial protocol.15 It is worth remembering that a non-randomised the trial will 
have to be analysed and reported very differently if randomisation is not a key 
component. All trials should be reported to CONSORT standards (CONSORT stands 
for Consolidated Standards of Reporting Trials) and it worth keeping these guidelines 
for reporting in mind during the design process.10 
 
A key question with RCTs is whether the randomisation is at an individual level or at 
a cluster level. The individually randomised parallel group design is typically seen as 
the standard RCT design and remains the favoured approach by funders. An 
example of an individually randomised parallel group design in dentistry is the 
FiCTION trial.5 This is appropriate IF the intervention is to be delivered to an 
individual and there is no possibility of contamination. However, this is not always 
possible. For example, if a community based oral health prevention programme was 
being delivered in a school, it would be difficult to undertake the intervention on one 
child and not affect another child. The environment in the school and the teachers 
that undertook the intervention would find it difficult not to influence a child in the 
control group. In such cases, cluster randomisation would be used. In this example, 
schools would be the unit of randomisation, not the individual (so a whole school 
would initiate the intervention and a whole school wouldn’t). Two examples of cluster 
randomised trials in dentistry are NIC-PIP and IQuaD.2,3 
 
Another design of definitive trial is a stepped wedge trial. Here, the unit of 
randomisation is not isn’t the individual or the cluster, but time. This might sound 
complex, but all this means is that everyone gets the intervention, but just not yet. 
These designs are not aren’t commonly used, but have the advantage that they map 
on well to a policy roll-out, where everyone will get the intervention. As a result, there 
are ethical advantages to the approach. For example, if a new practice prevention 
tool from Public Health England was going to be introduced across England and 
could be rolled out on a staggered basis, this approach could be undertaken. At 
specific time-points in the trial (the “step”), participating practices that are not yet 
adopting the intervention (who are currently acting as the control) come “on-line”. 
The down-side of stepped-wedge trials is that as each new wave of practices adopt 
the intervention, all the recruited practices in the trial have to have the POM 
measured again. Another disadvantage of this design is that you must have sufficient 
time between each step for the disease of interest to express itself. If this was a 
gingivitis measure, then this would not be too problematic, but if the researchers 
were examining the impact of the preventive intervention on dental caries in adults, 
this would mean that the trial would be very long. One example of a dental stepped 
wedge trial is the SOCLE-II trial.16 Here, researchers are exploring whether 
enhanced oral healthcare or usual oral healthcare is the most effective for people in 
stroke care settings. Rather than randomising the participants into the two groups, 
they are rolling out the intervention (enhanced oral healthcare), one ward at a time. 
More information on stepped-wedge trials can be found here.17,18  
 
How do you go about demonstrating your intervention has worked? 
A statistical hypothesis in a trial describes what the researcher expects to see 
happen to their chosen POM as their intervention is applied to the intervention arm. 
This assumption may or may not be true. The null hypothesis assumes that changes 
in the POM result from chance and that there is no difference between the 
intervention and the control arm. The alternate hypothesis assumes that changes are 
influenced by some non-random cause i.e. the intervention the researcher has 
introduced has worked!  
 
Individually, cluster and stepped-wedged designs commonly test a directional 
hypothesis that the new intervention produces a health benefit compared to the 
control or an existing intervention (“head-to-head”). These are termed “superiority 
designs” and from a statistical perspective, test whether your point estimate (mean if 
the POM is measured using a continuous variable) lies above or below the 95% 
confidence interval (CI) in the control arm. However, sometimes our question is 
whether a new treatment is as good as another treatment or meets a certain 
standard. Trials that explore these issues are known as “equivalence" or “non-
inferiority” designs. “Equivalence” trials determine whether the value for the POM in 
both arms is not statistically different i.e. that the 95% CI of the difference of the two 
groups lies within an acceptable margin (the equivalence margin). “Non-inferiority” 
designs test the difference between two arms and test whether the new intervention 
is not unacceptably worse than the other i.e. that the lower end 95% CI of the 
difference in POM does not extend below the pre-defined non-inferiority margin. 
More reading can be found here.19    
 
Statistical tests commonly quote the “p” value, which describes the statistical 
significance of the results. The p value is the probability that the difference between 
the scores would have happened by chance, therefore the lower the p value, the 
more likely that there is a significant difference between the scores. It is generally 
accepted that any POM being tested is statistically significant if the p value is below 
0.05. If this is the case, the null hypothesis can be rejected. However, it is worth 
knowing that the more times you test something, the more likely by chance you are 
going to find something statistically significant. In the cases of multiple testing, 
consideration should be given to adjusting the level of significance. 
 
How many participants do you need in your trial? 
There are three elements to a sample size calculation: the p-value, power and the 
effect size. The p-value is set commonly at 0.05 (as highlighted above). Power is the 
probability that you will see an effect IF an effect is there to be seen. Sometimes we 
don’t see a statistically significant effect because quite simply, no effect exists. 
However, sometimes an effect is there, but we don’t have the numbers to see it (this 
is called being under-powered). For RCTs, we set this probability of detecting an 
effect IF an effect is there to be seen at 90%. The only element that varies in the 
power calculation is the effect size i.e. this is the main element that the researcher 
needs to determine in consultation with a statistician. An effect size is a point 
estimate of the measure of the strength of effect standardised by the variability of the 
measure i.e. the expected difference in your POM between the intervention and 
control arm (for example, if your POM is measured using a continuous variable, this 
would commonly be the mean with the variability represented by the standard 
deviation). 
 
Table 1 and Table 2 provides you with the details that a statistician would need to 
know before a sample size can be calculated. More reading can be found here.20,21 
 
What about bias? 
Common to all trial designs is the need to reduce bias. A bias is a systematic error 
and can operate in either direction: under or over-estimating the true intervention 
effect. Bias is caused by flaws in the design of the study and so is not the same as 
imprecision, which is a random error. Selection bias refers to systematic differences 
between the intervention and control arm caused by differences in baseline 
characteristics. This should be removed if randomisation process was effective. 
Ensuring that participants are blind to their allocation (where possible) reduces the 
risk that knowledge of which intervention was received, rather than the intervention 
itself, affects the outcome. This is called allocation concealment. Detection bias (or 
ascertainment bias) refers to systematic differences produced by differences in how 
outcomes are determined. Blinding of outcome assessors may reduce the risk that 
knowledge of the intervention, rather than the intervention itself, affects the POM. 
Blinding of outcome assessors is especially important when subjective POMs are 
used, for example, how nervous were you during your dental treatment?  
 
Attrition bias describes the systematic differences between the intervention and 
control arm caused by withdrawals from the trial i.e. when the participants do not 
want to take part anymore. This can skew the numbers and mix of participants in 
each arm. It may also tell you that your trial is not socially acceptable! Reporting bias 
(or publication bias) refers to systematic differences caused by researchers and 
journals only reporting positive effects of intervention.22 This can be seen in the 
pharmaceutical industry where negative results about the effects of a particular drug 
can get hidden.23  
 
What are Clinical Trials Units 
Clinical Trials Units (CTUs) are “specialist units which have been set up with a 
specific remit to design, conduct, analyse and publish clinical trials and other well-
designed studies” (https://youtu.be/QvGaGEHgwXg).24 Commonly, they have a 
number of functional areas: 
 
• Statistical support (pre, per and post-trial) 
• Trial Management 
• Quality Assurance 
• Information Technology 
 
CTUs have expertise in the co-ordination of trials, particularly those that involve 
Investigational Medicinal Products, where compliance with the Medicines Health 
Regulatory Authority is critical to discharge the expectations in the “UK Medicines for 
Human Use (Clinical Trials) Regulations”.25 Some also provide specialist expert 
statistical for clinicians. For example, although NWORTH has over £18M of trials on 
its portfolio from across the United Kingdom, it is also part-funded by the Welsh 
Government to provide the Research Design and Conduct Service (http://nworth-
ctu.bangor.ac.uk/research-support-service/index.php.en).  
 
Most CTUs, but not all, are registered with the United Kingdom Clinical Research 
Collaboration (UKCRC) and many specialise in specific areas, like Clinical Trials of 
Investigative Medicinal Products (drug trials) or cancer trials. NWORTH has a 
traditional strength in pragmatic trials and trials of complex interventions. 
Methodologically, they link with initiatives like TrialForge (http://www.trialforge.org) 
and work to understand how to “make trials work” (see http://nworth-
ctu.bangor.ac.uk/trials.php). 
 
When preparing for a grant application, researchers are encouraged to approach 
CTUs early to get help on designing their project. The National Institute of Health 
Research sees CTUs “as an important component of any research application and 
funded project” and you are expected to inform them whether you have contacted a 
CTU in any grant application. They also provide a useful schematic of the necessary 
steps to take when planning a definitive trial (http://www.ct-toolkit.ac.uk). 
 
In summary 
This paper has explored the key design elements of RCTs. Although there are 
significant challenges encountered when designing such complex studies, thinking 
through each component described above will provide clarity and hopefully 
encourage more GDPs to get involved in research.26 This is important as there is an 
increasing need for high-quality evidence from primary care settings to guide the 
delivery of future healthcare.  
  
 
Table 1: Examples of PICO statements for recent/ongoing trials conducted in a primary care environment 
Trial Population Intervention Control/Comparator Clinical primary outcome 
measure 
Follow-up period 
iQuaD Regularly attending NHS 
dentate adult patients who have 
periodontal health, gingivitis or 
moderate periodontitis 
Personalized oral hygiene 
advice 
Standard oral hygiene advice Gingival inflammation/bleeding 
on probing at the gingival margin 
AND oral hygiene self-efficacy 
Three years 
NIC-PIP Children aged 2–3 years, who 
were caries free at baseline 
Fluoride varnish, a toothbrush 
and a 50-ml tube of adult 
toothpaste and standardized 
evidence-based prevention 
advice provided at 6-monthly 
intervals 
Prevention advice alone Proportion of children who 
converted from caries-free to 
caries-active states 
Three years 
INTERVAL Regularly attending NHS 
dentate adult patients 
Risk based recall interval based 
on the patient's risk of dental 
disease AND 
24 month recall interval 
6 month recall interval 
 
Gingival bleeding AND quality of 
life (OHIP-14) 
Four years 
FiCTION Children aged 3–7 years Conventional caries 
management with best practice 
prevention AND biological 
management of caries with best 
practice prevention  
Best practice prevention alone Incidence of either pain or 




Table 2: Statistical considerations when determining a sample size 
# Question 
1 How large do you expect the difference to be between the intervention and 
control group to be? Is this clinically significant i.e. a difference of 1mm in 
probing depth may be statistically significant, but is it really important in 
practice? If the effect size is small, the sample size will be large and vice versa. 
2 How much variation do you expect to see in the difference in the POM between 
the intervention and control arm? If the variability is small then the sample size 
will be small, whereas if the variability is large then the sample size will be 
large. 
3 What direction will the effect be? For example, do you think your intervention 
will produce a positive or negative difference in your POM, compared to the 
control (or will it be indifferent).  
4 Are you going to record the POM at baseline and at the end of your trial in the 
same participants (known as “repeated measures”) or in a different sample. The 
former is common with clinical interventions, whilst the latter is more common 
with public health interventions at a population level, where it is impractical to 
measure the same group of people at the end of the trial compared to at 
baseline. The latter requires a larger sample size. 
5 Are the same number of participants required in both the intervention and 
control arm, or are more participants are required in one group compared to the 
other. Unequal allocation to groups will require a larger sample size than equal 
allocation of groups. 
 
  
Table 3: Non-statistical considerations when determining a sample size 
# Question 
1 Can you recruit the number of participants required from the sample size 
calculation. This can be problematic, particularly with rare disorders. 
2 Is it “do-able” in terms of costs. The cost of the study needs to be considered 
and whether there will be sufficient funds to conduct a study with the number of 
participants required.  
3 How long does your study need to run for? This is linked to the “time to 
expression” of your POM. It is also influenced by how quickly you can recruit 
the numbers of participants that meet the eligibility criteria of your trial. 
4 Do you need to run a pilot/feasibility study first? Do you have enough 
information to reliably calculate a sample size? 
5 How many participants might withdraw from the study before the study is 
completed (attrition of the study). This depends on the study and the population 
of participants. As an example, if the study is in an elderly population then you 
would need to consider that participants may pass away before the study is 
completed. Remember there is a difference between withdrawing from a 
‘treatment’ and withdrawing from the study and data should be collected on all 







Figure 1: The experimental approach to evaluation 
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